Abstract
Kinins are blood-derived local-acting peptides that elicit specific cellular effects via the stimulation of two related G protein coupled receptors. While the B2 receptor subtype, constitutively expressed in various tissues, is believed to mediate most of the physiological actions of kinins in healthy conditions, the B1 receptor, highly regulated during inflammation, has been associated with the sustained actions of these peptides in various pathological situations. Potent peptide and nonpeptide modulators of both kinin receptors have been produced as pharmacological tools and potential therapeutics over the last three decades. More recently, the accumulating evidence suggesting that B1 receptor blockade could be useful for the treatment of pain and inflammatory disorders has led to a shift in drug development efforts toward the synthesis of orally bioavailable nonpeptide B1 receptor antagonists. Nonpeptide ligands of either receptor subtype produced by several industrial organizations often possess significant structural commonalities that can lead to the definition of a pharmacophore, especially when the receptor docking models are compared. The field of kinin receptors ligands research has reached an exciting step of its history, as the near future will reveal whether these molecules are therapeutically beneficial in various human diseases. This review will concisely summarize our current understanding of the biology of kinins and their receptors, before discussing the recent medicinal chemistry developments and challenges that bring new kinin receptor ligands closer to clinical applications.
Keywords: aminopeptidase, B-9958, GCPR, angiotensin II, docking site homology models
Current Topics in Medicinal Chemistry
Title: Advances in the Development of Bradykinin Receptor Ligands
Volume: 6 Issue: 13
Author(s): Jean-Philippe Fortin and Francois Marceau
Affiliation:
Keywords: aminopeptidase, B-9958, GCPR, angiotensin II, docking site homology models
Abstract: Kinins are blood-derived local-acting peptides that elicit specific cellular effects via the stimulation of two related G protein coupled receptors. While the B2 receptor subtype, constitutively expressed in various tissues, is believed to mediate most of the physiological actions of kinins in healthy conditions, the B1 receptor, highly regulated during inflammation, has been associated with the sustained actions of these peptides in various pathological situations. Potent peptide and nonpeptide modulators of both kinin receptors have been produced as pharmacological tools and potential therapeutics over the last three decades. More recently, the accumulating evidence suggesting that B1 receptor blockade could be useful for the treatment of pain and inflammatory disorders has led to a shift in drug development efforts toward the synthesis of orally bioavailable nonpeptide B1 receptor antagonists. Nonpeptide ligands of either receptor subtype produced by several industrial organizations often possess significant structural commonalities that can lead to the definition of a pharmacophore, especially when the receptor docking models are compared. The field of kinin receptors ligands research has reached an exciting step of its history, as the near future will reveal whether these molecules are therapeutically beneficial in various human diseases. This review will concisely summarize our current understanding of the biology of kinins and their receptors, before discussing the recent medicinal chemistry developments and challenges that bring new kinin receptor ligands closer to clinical applications.
Export Options
About this article
Cite this article as:
Fortin Jean-Philippe and Marceau Francois, Advances in the Development of Bradykinin Receptor Ligands, Current Topics in Medicinal Chemistry 2006; 6 (13) . https://dx.doi.org/10.2174/15680266106061353
DOI https://dx.doi.org/10.2174/15680266106061353 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Chemistry of Iodinated Contrast Media (ICM): A Mini Review
Mini-Reviews in Organic Chemistry Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Macrolides Allergy
Current Pharmaceutical Design Chronic Urticaria: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Serum Sickness Reaction to Rituximab with Positive Immediate Intradermal Skin Test: A Case Report
New Emirates Medical Journal Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
Current Cardiology Reviews Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Action Mechanism of Antihistamines and the New Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Mini-Thematic Issue: Mold Allergens and Antigenic Epitopes Correlation with Fungal Diseases)
Current Protein & Peptide Science Synthetic Thioamide, Benzimidazole, Quinolone and Derivatives with Carboxylic Acid and Ester Moieties: A Strategy in the Design of Antituberculosis Agents
Current Medicinal Chemistry Clopidogrel Hypersensitivity: Pathogenesis, Presentation and Diagnosis
Current Vascular Pharmacology Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advances in Inhibitors of FXa
Current Drug Targets